Alnylam Pharmaceuticals shares surged during the regular session, buoyed by positive developments in its clinical pipeline despite ongoing legal headwinds. The company announced that its collaborator, Regeneron, reported promising first-in-human results for the CIDEB siRNA program targeting MASLD, while simultaneously advancing its own ALN-4324 therapeutic into Phase II trials for Type 2 Diabetes. These clinical advancements helped provide a counter-narrative to the negative sentiment generated by a recent investor alert regarding a law firm investigation into the company's October 29 earnings report, which had previously highlighted slowing demand for the key drug Amvuttra.